Last updated: February 27, 2026
What is NDC 00781-7129?
NDC 00781-7129 refers to Humira (adalimumab), a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriatic arthritis. Approved by the FDA in 2002, Humira has been one of the top-selling drugs globally.
Market Landscape and Competitive Position
Market Size and Revenue
Humira dominated the biologic drug market for autoimmune conditions with peak sales exceeding $20 billion in 2021. Since patent expiration in January 2023, its market share faces pressure from biosimilars.
Biosimilar Competition
Bio-similars like Amjevita (Amgen) and Mimzi (Samsung Bioepis) entered the U.S. market in 2023, reducing Humira's exclusivity-driven revenue. The FDA approved multiple biosimilars, with market penetration varying by region.
Global Market Outlook
The global biologic market for autoimmune diseases was valued at approximately $130 billion in 2022, with an expected compound annual growth rate (CAGR) of around 8% through 2030. Humira’s sales are projected to decline with biosimilar competition, but persistent demand persists in combination therapies and markets outside the U.S.
Price Trends and Projections
U.S. Pricing Dynamics
- Pre-Patent Expiry: Humira’s list price per syringe was approximately $6,000 in 2022.
- Post-Patent Expiry: List prices have dropped by an estimated 50%, with biosimilars priced between $3,000 and $4,000.
Current Sale and Reimbursement
Private payers and Medicare Part D negotiate significant discounts, leading to actual costs below list prices. Average net prices have fallen by approximately 40-50% post-2023.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$4,500 |
Introduction of biosimilars |
| 2024 |
$4,000 |
Continued biosimilar market uptake |
| 2025 |
$3,600 |
Price stabilization then decline |
| 2026 |
$3,000 |
Biosimilar competition peaks |
| 2027 |
$2,800 |
Market consolidation |
Price reductions are driven by increased biosimilar market penetration and price negotiations; discounts are likely to Persist, especially in institutional settings.
Market Risks and Opportunities
Risks
- Delayed biosimilar adoption in certain regions due to patent disputes and patent thickets.
- Potential for new, more effective therapies emerging, reducing Humira's market share.
- Regulatory and reimbursement policies affecting pricing.
Opportunities
- Expansion into emerging markets with higher unmet medical needs.
- Development of biosimilars and next-generation biologics offering improved efficacy or delivery methods.
- Use of fixed-dose combinations to extend product lifecycle.
Key Competitors
- Amjevita (Amgen)
- Mimzi (Samsung Bioepis)
- Cyltezo (Boehringer Ingelheim)
- Hyrimoz (Sandoz)
Market share is expected to shift towards these biosimilars, with Humira maintaining revenue from legacy and niche indications.
Strategic Insights
- The revenue decline may be offset by increased volume in secondary markets.
- Price erosion emphasizes the importance of pipeline diversification.
- Continued government and payer negotiations will influence final net prices.
Conclusion
Humira’s market remains significant but is confronting substantial biosimilar competition, leading to modest price reductions and revenue declines over the next five years. Companies involved in manufacturing, distributing, or investing in these biologics should consider biosimilar uptake rates and regional regulatory environments.
Key Takeaways
- Post-patent expiration, list prices have halved from peak levels.
- Biosimilar competition sharply influences pricing and market share.
- Revenue projections show a steady decline but sustained demand in specific indications and regions.
- Growth opportunities lie in emerging markets and biosimilar pipeline development.
- Market risk factors include regulatory hurdles and the advent of new therapies.
FAQs
1. What is the primary driver of price decline for NDC 00781-7129?
The entry of biosimilars in 2023 and subsequent market penetration.
2. How does biosimilar pricing compare to the originator drug?
Biosimilars are priced approximately 30-50% lower, with list prices around $3,000-4,000 per dose compared to Humira’s previous $6,000 per syringe.
3. Which markets are most susceptible to biosimilar competition?
The U.S. and European markets, due to high adoption of biosimilars and payer negotiations.
4. What is the outlook for Humira’s revenue in the next five years?
Expected to decline 20-30% annually, stabilizing at lower levels with continued demand in specific indications.
5. How can pharmaceutical companies mitigate revenue declines?
By diversifying the product portfolio, investing in pipeline drugs, and expanding into emerging markets.
Citations
[1] EvaluatePharma. (2022). Biologic and biosimilar market data.
[2] FDA. (2023). Biosimilar approval announcements.
[3] IQVIA. (2022). Global biologic market analysis.
[4] Blink, T. (2023). Humira biosimilar pricing trends.
[5] Centers for Medicare & Medicaid Services. (2022). Medicare drug prices and discounts.
